New chelating agent reduces toxicity in prostate-specific membrane antigen radiopharmaceutical therapy
A newly developed chelator can significantly reduce off-target toxicity in prostate-specific membrane antigen (PSMA) radiopharmaceutical therapy, according to research presented at the 2024 Society of Nuclear Medicine and ...
Jun 11, 2024
0
0